Lauren Harmonay
Merck & Co., Inc., Rahway, NJ, USA (United States)(US)
Publications by Year
Research Areas
Advanced Breast Cancer Therapies, Cancer-related Molecular Pathways, Chronic Lymphocytic Leukemia Research, Catalytic Processes in Materials Science, Catalysts for Methane Reforming
Most-Cited Works
- → MCL1 and BCL-xL Levels in Solid Tumors Are Predictive of Dinaciclib-Induced Apoptosis(2014)53 cited
- → Pharmacological Inhibition of O-GlcNAcase Does Not Increase Sensitivity of Glucocorticoid Receptor-Mediated Transrepression(2015)7 cited
- → Kinetics of the Reactions of Cu(0) and Cu2O in Hexanes or Condensed Carbon Dioxide by tert-Butyl Peracetate and 1,1,1-Trifluoro-2,4-pentanedione(2006)4 cited
- → Abstract 699: Optimized dosing strategies resulting in prolonged pathway inhibition enhance dinaciclib anti-tumor activity in preclinical xenograft models.(2013)1 cited
- → Abstract 698: MCL1 dependent cells are sensitive to the CDK inhibitor Dinaciclib.(2013)